Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SAR408701 + ramucirumab in previously treated CEACAM5-positive metastatic non-squamous non-small cell lung cancer
2019-003914-15Phase 2Completed
- Sponsor
- Sanofi
- Start
- Mar 2020
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of tusamitamab ravtansine and ramucirumab in non-small cell lung cancer (NSCLC), sponsored by Sanofi. Primary endpoint: Incidence of study drug-related dose-limiting toxicity at Cycle 1 and Cycle 2. Started Mar 2020; status: completed.
02
Drugs
tusamitamab ravtansineramucirumab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on 2019-003914-15.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-003914-15.